Modeling the impact of one- and two-dose varicella vaccination on the epidemiology of varicella and zoster

Brisson, Marc; Melkonyan, G.; Drolet, Mélanie; Serres, Gaston De; Thibeault, Roseline; Wals, Philippe De

doi:10.1016/j.vaccine.2010.02.079

Cited by 86 publications

(112 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Brisson et al estimated that protection wanes by up to 3% per year, with the consequent risk of developing a breakthrough infection if exposed to VZV [31]. As has been suggested, a second dose offers additional protection and reduces the possibility of breakthrough cases [25,[32][33][34]. Our approach to vaccine effectiveness in vaccinated cohorts showed high effectiveness (96.8%) in a programme where most of children had received two doses.…”

Section: Discussionmentioning

confidence: 62%

“…Exposure to varicella might reduce the risk of zoster [37,38] and on the other hand, its absence would lead to an increase of herpes zoster [34,39]. Although this possible negative effect of the two-dose universal vaccination programme has not been taken into account in this study, recent studies have not demonstrated a relationship between varicella vaccination and increase of zoster disease in the general population [20,40,41].…”

Section: Discussionmentioning

confidence: 70%

See 1 more Smart Citation

Impact of universal two-dose vaccination on varicella epidemiology in Navarre, Spain, 2006 to 2012

et al. 2013

View full text Add to dashboard Cite

In 2007 in Navarre, Spain, universal varicella vaccination with two doses of Varivax was introduced in the childhood immunisation schedule for children aged 15 months and three years. This study describes changes in the epidemiology of varicella in the period 2006 to 2012 and evaluates vaccination effectiveness using epidemiological surveillance data. The incidence of varicella in children aged 0 to 14 years decreased by 98.1%, from 50.1 cases per 1,000 inhabitants in 2006, to 1.0 per 1,000 in 2012. Children aged one to eight years were the vaccinated cohorts, and their incidence of varicella decreased by 98.5% (p<0.0001). In unvaccinated age groups, important reductions were also achieved between 2006 and 2012: 90.5% (p<0.0001) in infants under one year of age, and 89.4% (p<0.0001) in children aged nine years. In the period 2006 to 2012, the hospital admissions rate for varicella or its complications decreased by 89.0%, and in 2012, there was only one admission of a newborn with neonatal varicella. Vaccine effectiveness for at least one dose was 96.8% (95% confidence interval: 96.3-97.2%). Universal vaccination with two doses has reduced varicella circulation to minimum levels within five years and has proved highly effective.

show abstract

Section: Discussionmentioning

confidence: 62%

Section: Discussionmentioning

confidence: 70%

Impact of universal two-dose vaccination on varicella epidemiology in Navarre, Spain, 2006 to 2012

et al. 2013

View full text Add to dashboard Cite

show abstract

“…Accordingly to the exogenous boosting theory, the decrease of the spreading of wildtype VZV following universal immunization, should decrease the opportunities to have VZV-specific CMI boosted and should cause, at least for some decades, an increase of HZ cases in unvaccinated subjects. 56 Other authors support the endogenous booster hypothesis, accordingly to which latent VZV could silently reactivate and boost VZV-specific CMI. Endogenous boosting is very difficult to evaluate and demonstrate; anyway, VZV latency in enteric neurons and the following possible silent reactivation could lead, at least for some time, to long-term protection and maintenance of VZV-specific CMI.…”

Section: Can Zoster Vaccine Be Co-administered To Other Vaccines?mentioning

confidence: 88%

Prevention of Herpes Zoster and its complications: From clinical evidence to real life experience

Gabutti

Bonanni

Conversano³

et al. 2016

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

Herpes zoster (HZ) is an acute viral illness characterized by a vesicular rash with unilateral distribution, which can also result in severe complications such as post-herpetic neuralgia (PHN), ophthalmic zoster, stroke or other neurological complications. The estimate incidence in Europe ranges between 2.0 and 4.6 cases per 1,000 person-years, with a sharp increase in >50 year-old subjects. Currently, treatment options for HZ are only partially effective in limiting the acute phase, while the management of complications is complex and often unsatisfactory. The total burden of the disease and the high costs related to its diagnostic and therapeutic management led researchers to develop a new preventive approach through a live attenuated virus vaccine. The currently available vaccine, with a high antigen content, is safe, well tolerated and reduces the incidence of HZ, PHN and the burden of illness. Several countries have introduced this vaccination, albeit with different recommendations and methods of financing. Taking into account the barriers to this immunization registered in some areas (difficulty of vaccine distribution, lack of physician recommendations, the cost of vaccine for patients, etc.), this group of Italian experts advocate that a common strategy able to guarantee a good compliance with this vaccination should be implemented. The same group addresses some practical questions concerning the use of zoster vaccine.

show abstract

“…Exposure to exogenous VZV protects against zoster and/or boosts cellular immunity 26,27 . Although mathematical modelling has predicted an increase in zoster where circulating VZV is reduced by childhood vaccination programmes 28 , the concept of exogenous VZV exposure as the only means for immune boosting remains an area of controversy (see below). Postlicensure surveillance data provide direct evidence of the impact of the varicella vaccine on zoster epidemiology 29,30 .…”

Section: Zostermentioning

confidence: 99%

Varicella zoster virus infection

Suzuki

Suga²,

Asano³

2015

Nat Rev Dis Primers

View full text Add to dashboard Cite

Modeling the impact of one- and two-dose varicella vaccination on the epidemiology of varicella and zoster

Cited by 86 publications

References 42 publications

Impact of universal two-dose vaccination on varicella epidemiology in Navarre, Spain, 2006 to 2012

Impact of universal two-dose vaccination on varicella epidemiology in Navarre, Spain, 2006 to 2012

Prevention of Herpes Zoster and its complications: From clinical evidence to real life experience

Varicella zoster virus infection

Contact Info

Product

Resources

About